| Followers | 1440 |
| Posts | 30250 |
| Boards Moderated | 26 |
| Alias Born | 12/10/2012 |
Tuesday, April 15, 2025 8:52:41 AM
$MURA: Tapped $2.20
Wellllllllllllllllllll done
GO $MURA
Wellllllllllllllllllll done
GO $MURA
Recent MURA News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/09/2025 05:15:09 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 12/05/2025 09:35:34 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/05/2025 09:30:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2025 02:10:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 01:22:59 PM
- Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition • GlobeNewswire Inc. • 12/05/2025 12:45:00 PM
- Mural Oncology Announces Sanction of the Scheme by the High Court • GlobeNewswire Inc. • 12/03/2025 09:30:00 PM
- Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty • GlobeNewswire Inc. • 11/26/2025 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 01:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 08:35:09 PM
- Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty • GlobeNewswire Inc. • 10/24/2025 08:25:31 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/17/2025 08:08:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/06/2025 12:00:57 PM
- Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting • GlobeNewswire Inc. • 09/23/2025 11:52:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2025 09:20:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2025 09:19:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2025 09:18:00 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 09/23/2025 09:16:55 PM
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 09/12/2025 09:16:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/20/2025 12:53:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 12:50:42 PM
- Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share • GlobeNewswire Inc. • 08/20/2025 12:30:00 PM
